Long-term clinical outcomes of patients on danazol. (A) CONSORT diagram from initial enrollment on study, study completion, and post-protocol follow-up. One patient from the 27 enrolled was deemed nonevaluable due to subsequent Fanconi anemia diagnosis. (B) Time to loss of hematologic response after danazol discontinuation per protocol. (C) OS of the patients on the danazol study with long-term follow-up. (D) A swimmer diagram indicating hematologic response (blue) or lack of hematologic response (red) to danazol (green line overlayed). A gray bar indicates hematologic response is nonevaluable, such as if there was remote follow-up or post-hematopoietic stem cell transplant (HSCT). Events indicated are chromosomal abnormalities, MDS/myelodysplastic neoplasm development, HSCT, liver transplant, lung transplant, adverse events, and death.